| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 104.85 | 2.5% | 7.4% |
| Total Income | 104.85 | 2.5% | 7.4% |
| Expenditure | 113.93 | 0.1% | 1.5% |
| PBT | -11.34 | 14.1% | 1250.0% |
| Net Profit | -11.81 | 14.2% | 808.5% |
| OPM | -8.67% | 2.64pp | 9.59pp |
| NPM | -11.26% | 2.21pp | 10.11pp |
| EPS | -0.09 | 18.2% | 800.0% |
Accuray Reports Q3 FY26 Revenue $104.8 Million, Down 7% Y-o-Y
07 May 2026 · 7 May, 1:45 am
Summary
Accuray reported a decrease in total net revenue for Q3 FY26, amounting to $104.8 million, a 7% decrease compared to the prior year. Product revenue decreased by 13% to $49.7 million, while service revenue saw a slight decrease of 1% to $55.1 million. The company's transformation plan is progressing well, with $10 million in cost and margin improvements achieved. Due to geopolitical uncertainty in the Middle East, Accuray has withdrawn its fiscal year 2026 financial guidance.
Key Highlights
- 1
Accuray's transformation plan is delivering ahead of expectations, achieving approximately $10 million of cost and margin improvements through Q3 FY26.
- 2
Total net revenue was $104.8 million in Q3 FY26, a decrease of 7 percent compared to $113.2 million in the prior fiscal year third quarter.
- 3
Product revenue decreased by 13 percent to $49.7 million in Q3 FY26, compared to $57.3 million in the prior fiscal year third quarter.
- 4
Service revenue was $55.1 million in Q3 FY26, a decrease of 1 percent compared to $55.9 million in the prior fiscal year third quarter.
- 5
The company withdraws fiscal 2026 financial guidance due to geopolitical uncertainty in the Middle East.
- 6
Order backlog as of March 31, 2026, was $356.2 million, approximately 21% lower than at the end of the prior fiscal year third quarter.
- 7
Net loss was $11.8 million in Q3 FY26, or a diluted net loss of $0.09 per share, compared to a net loss of $1.3 million in the prior fiscal year third quarter.
Management Comments
Steve LaNeve
“During the quarter, we made meaningful progress executing against the transformation plan we launched in December. We are already seeing tangible benefits from these initiatives, including approximately $10 million in realized margin improvements through the fiscal third quarter, positioning us ahead of our original expectations. We have also strengthened our leadership team with experienced talent in key strategic areas and continue to enhance our technology platform through highly strategic partnerships focused on advancing real-time adaptation to patient and tumor motion during treatment, a core differentiator of Accuray’s technology. Taken together, we believe these actions will improve execution, strengthen profitability, and create meaningful long-term value for our shareholders.” Mr. LaNeve continued, “Overall, we are encouraged by the progress we are making and remain confident in our strategy and our ability to execute on the areas within our control. However, the current geopolitical environment has created significant unpredictability around the timing of installations in several key Middle Eastern markets. Given these uncertainties, we believe it is prudent to withdraw financial guidance at this time, specifically as it relates to total net revenue and Adjusted EBITDA, and revisit our outlook when we report fiscal fourth quarter results.”
Informational and educational content only. Not investment advice.